Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)

被引：0
|
作者：
Berton-Rigaud, D. [1 ,2 ]
Pautier, P. [3 ,4 ]
Lorusso, D. [5 ,6 ]
Gennigens, C. [7 ]
Gladieff, L. [8 ,9 ]
Kryzhanivska, A. [10 ]
Bowman, J. [11 ]
Tian, C. [12 ]
Cornfeld, M.
Van Gorp, T. [13 ]
机构：
[1] GINECO, Serv Oncol Med, St Herblain, France
[2] Inst Cancerol IOuest ICO, St Herblain, France
[3] GINECO, Dept Med, Villejuif, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Fdn Policlin Univ Agostino Gemelli, Gynecol Oncol Unit, Rome, Italy
[6] Univ Cattolica Sacro Cuore, Rome, Italy
[7] Ctr Hosp Univ Sart Tilman, Oncol Gynecol Unit, Liege, Belgium
[8] GINECO, Med Oncol Dept, Toulouse, France
[9] Inst Claudius Regaud IUCT Oncopole, Toulouse, France
[10] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine
[11] Incyte Corp, Immuno Oncol, Wilmington, DE USA
[12] Incyte Corp, Biostat, Wilmington, DE USA
[13] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol, Div Gynaecol Oncol, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1934
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
755P
引用
收藏
页码：S517 / S517
页数：1
相关论文
共 50 条
  • [31] Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
    Tinker, A. V.
    Pothuri, B.
    Gilbert, L.
    Sabatier, R.
    Brown, J.
    Ghamande, S.
    Mathews, C.
    O'Malley, D.
    Boni, V.
    Gravina, A.
    Banerjee, S.
    Miller, R.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S798 - S799
  • [32] Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
    Liao, Ying
    Zhu, Changhua
    Song, Xiaoxia
    Ruan, Jiugen
    Ding, Yao
    Chen, Yuan
    Yang, Qiujuan
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [33] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [34] Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
    Chakrabarti, Sakti
    Selfridge, J. Eva
    Parish, Marie
    Bajor, David L.
    Ruggeri, Antony
    Tolay, Sameer
    Conces, Madison
    Lumish, Melissa Amy
    Mohamed, Amr
    Mahipal, Amit
    Shreenivas, Aditya V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 736 - 736
  • [35] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
  • [36] Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    Acosta, A. De Jesus
    Miller, W. H., Jr.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Xu, L.
    Jin, F.
    Norwood, K.
    Maio, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S730 - S731
  • [37] Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer
    Kawaguchi, Makiko
    Banno, Kouji
    Yanokura, Megumi
    Kobayashi, Yusuke
    Kishimi, Arisa
    Ogawa, Seiji
    Kisu, Iori
    Nomura, Hiroyuki
    Hirasawa, Akira
    Susumu, Nobuyuki
    Aoki, Daisuke
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (05) : 977 - 982
  • [38] Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H)
    Kanbour, Aladdin
    Rasul, Kakil Ibrahim
    Albader, Salha Bujassoum
    Al Sulaiman, Reem Jawad
    Melikyan, Gayan
    Farghaly, Hanan
    Lengyel, Zsolt
    Al Rimawi, Yousef
    Soliman, Dina
    Omar, Nabil Elhadi
    ONCOTARGETS AND THERAPY, 2019, 12 : 9965 - 9973
  • [39] Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
    Valabrega, G.
    Powell, M. A.
    Hietanen, S.
    Miller, E. M.
    Novak, Z.
    Holloway, R.
    Denschlag, D.
    Myers, T.
    Thijs, A. M.
    Pennington, K.
    Gilbert, L.
    Fleming, E.
    Copeland, L.
    Gogoi, R.
    Podzielinski, I.
    Cloven, N.
    Meyers, O.
    Garside, J.
    Mirza, M. R.
    Black, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S513 - S514
  • [40] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
12345